Kite, A Gilead Company

This early-phase study tests experimental cell therapies in 40 people with multiple myeloma that has returned or not responded to at least three prior treatments. The main goals are to check safety and find the best dose. Participants must have measurable disease and adequate org…

This early-phase study is testing a new treatment called KITE-363 for people with severe autoimmune diseases like lupus, scleroderma, and inflammatory myopathy that haven't improved with standard therapies. KITE-363 uses a patient's own immune cells, which are modified in a lab t…

This early-stage study tests a new treatment called KITE-197 for people with a type of blood cancer (large B-cell lymphoma) that has come back or not responded to other treatments. The study has two parts: first, to find a safe dose, and second, to see how well that dose works at…

This study tests a new treatment called CART-ddBCMA for people with multiple myeloma that has come back or not responded to at least three prior treatments. The therapy uses a patient's own immune cells, modified to target and kill cancer cells. The main goal is to see how many p…

This study tests a treatment called KTE-X19, a type of cell therapy that uses a patient's own immune cells to fight cancer. It is for Japanese adults with two types of blood cancer that have come back or not responded to other treatments: mantle cell lymphoma and B-cell acute lym…

This study follows up to 1,000 people who previously received gene-modified cell therapy for blood or solid cancers in Kite-sponsored trials. Researchers will watch for late side effects, track growth in children, and see how long the treatment's effects last. The goal is to bett…